Sürekli ayaktan periton diyalizi hastalarında düşük anti-HCV prevalansı: Nosokomiyal geçisin önemi

Ünitemizde hemodiyaliz (HD) ve sürekli ayaktan periton diyalizi (SAPD) uygulanan hastalarda anti-HCV sıklığının karşılaştırılması. Yöntem: Araştırma 89 HD, 45 SAPD hastası üzerinde yapıldı. Kırkbeş hastadan 15'ine SAPD'ye primer tedavi olarak başlanırken, diğer 30 hasta HD'den SAPD'ye transfer edilmişti. Sadece SAPD uygulanan hastalarla karşılaştırmak üzere, randomize olarak diyaliz süresi bakımından uygun olan 16 HD hastası seçildi. Anti-HCV tayini için üçüncü jenerasyon enzim immunoassay yöntemi kullanıldı. Bulgular: Hemodiyaliz grubu ve SAPD grubu arasında yaş, diyaliz süresi ve transfüzyon sayıları bakımından istatistiksel fark yokken, anti-HCV sıklığı SAPD grubunda anlamlı olarak daha düşük bulundu (sırasıyla % 2.2 ve % 19.1, P=0.006). Yine SAPD alt grubu ve HD alt grubu arasında yaş, diyaliz süresi ve transfüzyon sayıları bakımından anlamlı fark yokken, SAPD alt grubundaki tüm hastaların anti-HCV'leri negatif bulundu. Hemodiyaliz alt grubunda ise 3 hastada (% 18.8) anti-HCV (+) bulundu. Sonuç: SAPD grubunda anti-HCV prevalansı HD hasta grubuna göre anlamlı derecede daha düşüktür. Gruplar arasında ortalama transfüzyon sayıları bakımından fark olmaması, HD hastalarındaki artmış anti-HCV prevalansından primer olarak nosokomiyal geçişin sorumlu olabileceğini düşündürmektedir.

Lower anti-HCV prevalence in CAPD patients: The importance of nosocomial transmission

We aimed to compare anti-HCV prevalence in HD and CAPD patients in our unit. Methods: CAPD was primary therapy in 15 patients, while other 30 patients were transferred from HD to CAPD. To compare with the patients being applied only CAPD, 16 HD patients who had appropriate dialysis duration were chosen randomly. Third generation enzyme immunoassay method was used for anti-HCV determination. Results: There was no significant difference between HD and CAPD groups with respect to anti-HCV prevalence, age, dialysis duration and transfusion number. Anti-HCV prevalence was lower in CAPD group (2.2% and 19.1%, respectively, P = 0.006). There was also no significant difference between the CAPD and HD subgroups with respect to anti-HCV prevalence, age, dialysis duration and transfusion number. Anti-HCV was found to be negative in all patients of the CAPD subgroup. In 3 patients (18.8%) of the HD subgroup anti-HCV was positive. Conclusion: Anti-HCV prevalence in CAPD patients was lower than that of HD patients. Considering no difference between the two groups with respect to transfusion number, it has been suggested that nosocomial transmission may be responsible for increased anti-HCV prevalence in HD patients.

___

  • Blumberg A, Zehnder C, Burckhardt JJ. Prevention of hepatit C infection in haemodialysis units: A prospective study. Nephrol Dial Transplant 1995;10:230-3.
  • Calabrase G, Vagelli G, Guaschino R, Gonella M. Transmission of anti-HCV within the household of haemodialysis patients. Lancet 1991;338:1446.
  • Dussol B, Bertheze P, Brunet P, Roubicek C, Berland Y. Hepatitis C virus infection among chronic dialysis patient in south of France: A collaborative study. Am J Kidney Dis 1995;25:399-404.
  • Pereira BJG, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-99.
  • Dussol B, Berthezene P, Brunet P, Berland Y. Hepatitis C virus infection among chronic dialysis patients in the south-east of France. Nephrol Dial Transplant 1995;10:477-8.
  • McIntrye PG, McCruden EA, Dow BC, Cameron SO, McMilan MA, Allison ME, et al. Hepatitis C virus infection in renal dialysis patients in Glascow. Nephrol Dial Transplant 1994;9:291-5.
  • Chan TM, Lok ASF, Cheng IKF. Hepatitis C virus infection among dialysis patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991;6:944-7.
  • Brugnano R, Francisci D, Quintaliani G, Gabucci M, Nori G, Verdura C, et al. Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: Evaluation of some risk factors. Nephron 1992;61:263-5.
  • Akpolat T, Arik N, Gunaydın M, Utas C, Dilek K, Caglar S, et al. Prevalance of anti-HCV among haemodialysis patients in Turkey: A multicenter study. Nephrol Dial Transplant 1995;10:479-0.
  • Pinto dos Santos J, Loureiro A, Cendoroglo M, Pereire BJG. Impact of dialysis room and reuse strategies on incidence of HCV infection in hemodialysis units. Nephrol Dial Transplant 1996;11:2017-22.
  • Fabrizi F, Lunghi G, Guarnori I, Raffaele L, Erba G, Pagano A et al. Hepatitis C virus genotypes in choronic dialysis patients (short report). Nephrol Dial Transplant 1996;11:679-83.
  • Gültekin M, Süleymanlar İ, Baykal. Hepatit C virusu (HCV) enfeksiyonu tanısında kullanılan çeşitli yöntemlerin değerlendirilmesi. Viral Hepatit Derg 1996;8:1164-73.
  • Gilli P, Moretti M, Soffritti S, Menini C. Anti-HCV positive patients in dialysis unit. Lancet 1990;336:187-8.
  • Pascual J, Teruel JL, Liano F, Ortuno J. Home hemodialysis protects against hepatitis C virus transmission. Nephron 1993;64:314.
  • Gili P, Moretti M, Soffritti S, Marchi N, Malacorne F, Bedani PL, et al. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs 1990;13:737-41.
  • Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on dialysis. Clin Nephrol 1992;38:44-8.
  • Huang CC, Wu MS, Lin DY, Liaw YF. The prevalance of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis. Peritoneal Dial Int 1992;12:31-3.
  • Sampietro M, Badalamenti S, Salvadori S, Corbetta N, Graziani G, Como G, et al. High prevalence of a rare hepatit C virus in patients treated in the same hemodialysis unit: Evidence for nosocomial transmission of HCV. Kidney Int 1995;47:3:911-7.
  • Gili P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. Nephron 1995;70:301-6.